Kamada (KMDA) Expected to Release Earnings on Monday

Kamada (NASDAQ:KMDA) is anticipated to issue its Q3 2026 results before the market opens on Monday, November 9th. Analysts expect Kamada to announce earnings of $0.13 per share and revenue of $52.51 million for the quarter. Investors may visit the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Monday, November 9, 2026 at 8:30 AM ET.

Kamada (NASDAQ:KMDA) last posted its quarterly earnings data on Wednesday, August 12th. The biotechnology company reported $0.16 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.05. The company had revenue of $54.92 million during the quarter, compared to analysts’ expectations of $50.84 million. Kamada had a return on equity of 8.37% and a net margin of 11.60%. On average, analysts expect Kamada to post $0.48 EPS for the current fiscal year and $0.58 EPS for the next fiscal year.

Kamada Price Performance

Shares of KMDA stock opened at $7.70 on Monday. Kamada has a one year low of $6.55 and a one year high of $9.35. The stock has a market cap of $442.83 million, a P/E ratio of 20.26, a price-to-earnings-growth ratio of 0.65 and a beta of 0.90. The stock has a fifty day moving average price of $8.19 and a 200 day moving average price of $8.02.

Kamada Cuts Dividend

The company also recently disclosed an annual dividend, which was paid on Thursday, September 17th. Stockholders of record on Thursday, August 27th were issued a dividend of $0.17 per share. The ex-dividend date of this dividend was Thursday, August 27th. This is a negative change from Kamada’s previous annual dividend of $0.25. This represents a dividend yield of 206.0%. Kamada’s dividend payout ratio (DPR) is 34.21%.

Wall Street Analyst Weigh In

Several brokerages have recently commented on KMDA. William Blair set a $15.00 target price on Kamada in a report on Tuesday, July 21st. Benchmark reaffirmed a “buy” rating on shares of Kamada in a report on Tuesday, July 21st. UBS Group restated a “buy” rating and set a $15.00 target price on shares of Kamada in a research report on Friday, September 18th. Weiss Ratings upgraded Kamada from a “buy (b-)” rating to a “buy (b)” rating in a research report on Friday, October 9th. Finally, Wall Street Zen raised shares of Kamada from a “hold” rating to a “strong-buy” rating in a research note on Saturday, August 15th. Four equities research analysts have rated the stock with a Buy rating. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $13.50.

Kamada Company Profile

Kamada Ltd. is a biopharmaceutical company focused on the development, manufacturing and commercialization of plasma-derived therapeutics and specialty pharmaceutical products. The company uses its expertise in plasma protein purification to address rare diseases, immune deficiencies and other serious medical conditions.

Kamada’s portfolio includes GLASSIA, an intravenous alpha-1 antitrypsin therapy used as augmentation treatment for adults with severe alpha-1 antitrypsin deficiency and emphysema.